{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:26:16Z","timestamp":1787009176988,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,31]]},"DOI":"10.1093\/jsxmed\/qdad083","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T10:46:11Z","timestamp":1686134771000},"page":"1057-1059","source":"Crossref","is-referenced-by-count":7,"title":["A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie\u2019s disease: the first clinical signals"],"prefix":"10.1093","volume":"20","author":[{"given":"Selim","family":"Cellek","sequence":"first","affiliation":[{"name":"Fibrosis Research Group , Medical Technology Research Centre, , Chelmsford CM1 1SQ , United Kingdom"},{"name":"Anglia Ruskin University , Medical Technology Research Centre, , Chelmsford CM1 1SQ , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Megson","sequence":"additional","affiliation":[{"name":"Fibrosis Research Group , Medical Technology Research Centre, , Chelmsford CM1 1SQ , United Kingdom"},{"name":"Anglia Ruskin University , Medical Technology Research Centre, , Chelmsford CM1 1SQ , United Kingdom"},{"name":"Urology Department, University College London Hospital , London W1G 8PH , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus M","family":"Ilg","sequence":"additional","affiliation":[{"name":"Fibrosis Research Group , Medical Technology Research Centre, , Chelmsford CM1 1SQ , United Kingdom"},{"name":"Anglia Ruskin University , Medical Technology Research Centre, , Chelmsford CM1 1SQ , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Ralph","sequence":"additional","affiliation":[{"name":"Fibrosis Research Group , Medical Technology Research Centre, , Chelmsford CM1 1SQ , United Kingdom"},{"name":"Anglia Ruskin University , Medical Technology Research Centre, , Chelmsford CM1 1SQ , United Kingdom"},{"name":"Urology Department, University College London Hospital , London W1G 8PH , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"2023080101551015100_ref1","first-page":"55","article-title":"Peyronie\u2019s disease: an outcomes-based guide to non-surgical and novel treatment modalities","volume":"15","author":"Reddy","year":"2023","journal-title":"Res Rep Urol"},{"issue":"4","key":"2023080101551015100_ref2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.sxmr.2019.02.004","article-title":"Pathophysiology and future therapeutic perspectives for resolving fibrosis in Peyronie\u2019s disease","volume":"7","author":"Milenkovic","year":"2019","journal-title":"Sex Med Rev"},{"key":"2023080101551015100_ref3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41443-021-00469-w","article-title":"Is there a line between ethics and market competition? Lights and shades of the withdrawal of collagenase treatment for Peyronie\u2019s disease","volume":"34","author":"Cocci","year":"2022","journal-title":"Int J Impot Res"},{"key":"2023080101551015100_ref4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.sxmr.2021.12.005","article-title":"Clinical significance of shortened penile length and alterations in penile length following treatment for Peyronie\u2019s disease","volume":"10","author":"Goldstein","year":"2022","journal-title":"Sex Med Rev"},{"key":"2023080101551015100_ref5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41443-020-0324-7","article-title":"Trends in reported male sexual dysfunction over the past decade: an evolving landscape","volume":"33","author":"Pozzi","year":"2021","journal-title":"Int J Impot Res"},{"key":"2023080101551015100_ref6","article-title":"A systematic review of non-surgical management in Peyronie\u02bcs disease","volume":"113","author":"Hayat","year":"2022","journal-title":"Int J Impot Res"},{"key":"2023080101551015100_ref7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000522417","article-title":"Metabolic regulation of fibroblast activation and proliferation during organ fibrosis","volume":"8","author":"Wang","year":"2022","journal-title":"Kidney Dis (Basel)."},{"key":"2023080101551015100_ref8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277646","article-title":"Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie\u2019s disease","volume":"17","author":"Ilg","year":"2022","journal-title":"PLoS One"},{"key":"2023080101551015100_ref9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","article-title":"Treatment of Peyronie\u2019s disease with PDE5 inhibitors: an antifibrotic strategy","volume":"7","author":"Gonzalez-Cadavid","year":"2010","journal-title":"Nat Rev Urol."},{"key":"2023080101551015100_ref10","doi-asserted-by":"crossref","DOI":"10.1038\/s41443-022-00651-8","article-title":"Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie\u2019s disease: a retrospective comparative analysis","author":"Spirito","year":"2022","journal-title":"Int J Impot Res."},{"key":"2023080101551015100_ref11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","article-title":"Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie\u2019s disease and erectile dysfunction: results from a prospective randomized trial","volume":"35","author":"Palmieri","year":"2012","journal-title":"Int J Androl."},{"key":"2023080101551015100_ref12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5534\/wjmh.2016.34.1.40","article-title":"The efficacy of medical treatment of Peyronie\u2019s disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor","volume":"34","author":"Park","year":"2016","journal-title":"World J Mens Health"},{"key":"2023080101551015100_ref13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/0974-7796.152048","article-title":"Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie\u2019s disease","volume":"7","author":"Dell\u2032Atti","year":"2015","journal-title":"Urol Ann"},{"key":"2023080101551015100_ref14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","article-title":"Effects of sildenafil treatment on patients with Peyronie\u2019s disease and erectile dysfunction","volume":"183","author":"Ozturk","year":"2014","journal-title":"Ir J Med Sci"},{"key":"2023080101551015100_ref15","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1590\/s1677-5538.ibju.2016.06.02","article-title":"Data vs dogma in Peyronie\u2019s disease","volume":"42","author":"Terlecki","year":"2016","journal-title":"International Braz J Urol"},{"key":"2023080101551015100_ref16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","article-title":"The treatment of Peyronie\u2019s disease with tamoxifen","volume":"70","author":"Ralph","year":"1992","journal-title":"Br J Urol"},{"key":"2023080101551015100_ref17","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","article-title":"Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease","volume":"162","author":"Teloken","year":"1999","journal-title":"J Urol"},{"key":"2023080101551015100_ref18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsxm.2020.06.022","article-title":"Phosphodiesterase type 5 inhibitors and selective estrogen receptor modulators can prevent but not reverse myofibroblast transformation in Peyronie\u2019s disease","volume":"17","author":"Ilg","year":"2020","journal-title":"J Sex Med"},{"key":"2023080101551015100_ref19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2018.10.014","article-title":"Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie\u2019s disease models","volume":"75","author":"Ilg","year":"2019","journal-title":"Eur Urol"},{"key":"2023080101551015100_ref20","volume-title":"Prescribing unlicensed medicines (from Good Practice in Prescribing and Managing Medicines and Devices)","author":"General Medical Council","year":"2023"},{"key":"2023080101551015100_ref21","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jsxm.2022.08.158","article-title":"Can tamoxifen and a PDE5 inhibitor slow the progression of Peyronie\u2019s disease?","volume":"19","author":"Megson","year":"2022","journal-title":"J Sex Med"},{"key":"2023080101551015100_ref22","volume-title":"Treatment of acute phase of Peyronie\u2019s disease with tamoxifen and tadalafil off label","author":"Geelhoed","year":"2023"},{"key":"2023080101551015100_ref23","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie\u2019s disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J Urol"},{"key":"2023080101551015100_ref24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","article-title":"A retrospective review of 307 men with Peyronie\u2019s disease","volume":"168","author":"Kadioglu","year":"2002","journal-title":"J Urol"},{"key":"2023080101551015100_ref25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01664","article-title":"On-label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients","volume":"10","author":"Verbaanderd","year":"2020","journal-title":"Front Pharmacol"},{"key":"2023080101551015100_ref26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.ijir.3900877","article-title":"Clinical presentations of Peyronie\u2019s disease","volume":"14","author":"Pryor","year":"2002","journal-title":"Int J Impot Res"},{"key":"2023080101551015100_ref27","first-page":"107","volume":"7","author":"Paulis","year":"2015","journal-title":"Res Rep Urol."}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/20\/8\/1057\/51007769\/qdad083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/20\/8\/1057\/51007769\/qdad083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T21:55:47Z","timestamp":1690840547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/20\/8\/1057\/7218889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,7,4]]},"published-print":{"date-parts":[[2023,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdad083","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,7,4]]}}}